Solving Drug Discovery with Metabolomics and Metabonomics

Published February 2005
There has been an 'omics' explosion. With the advent of genomics, proteomics, transcriptomics, there is also now metabolomics and metabonomics. These terms are the newest sibling to genomics and proteomics and are supposed to embody metabolic profiling.

Metabonomics is defined as measurement of the complete metabolic response of an organism to an environmental stimulus or genetic modification. Some people use the term metabolomics to refer to metabonomics at the level of a single cell type, rather than a larger system. In this report we will use both terms interchangeably.

Scope
This Report will analyze the biochemical nature of metabolomics, the technologies behind metabolomics, metabonomics related approaches, and the appropriate market potentials. This Report highlights new developments in chemical network (biochemical pathways) technology and the analytical tools developed to facilitate drug discovery.

The Report provides market trends and evaluates metabolonomic pertaining to the pharmaceutical industry and the potential of being applied in the areas of drug discovery and development, and preventive screening/diagnostics. In addition, this Report indicates target compound analysis by discussing methods that measure the quantification of specific metabolites. Profiles of the major players in the metabolomics/metabonomics and systems biology field are also included.

Key Reasons to Buy
* Knowledge derived from global metabolomics studies provides information about potential disease markers or a pattern of discrete biomarkers and can also assist in determining efficacy and toxicity data at a preclinical l level.
* Identify commercial opportunities for metabolomic-based drug and diagnostic technologies via a thorough assessment of current and emerging drug development platforms, including particular diagnostics utilized to discover novel cytokine-targeted drugs.
* Obtain a complete and extensive appraisal of the development status for metabolomic and metabonomic equipment, techniques, software, databases and applications; as well as pinpoint the position of metabolomics in the family of 'omic' disciplines.
* Provide a detailed analysis of the current fingerprinting techniques that are being used in metabolomic studies.
* Discuss cutting edge high throughput drug screening methodologies and the encouraging results of initial screening/ diagnostic platforms in diseases
* Look inside 25 companies active in the metabolomics/metabonomics market including their strategic alliances, products and pipelines, financial status, and more.

Market Opportunities
* The metabonomic profile represents a frozen view in time of the output as small molecules from on-going biological processes, which can then be used in the mining of metabolic profiles for biomarkers.
* The presence of a metabolite, panel of metabolites, or of a certain ratio of metabolites, can be an indication of a particular disease. This creates opportunities for early detection, ideally before the physical symptoms of a disease can be observed.
* Knowledge of metabonomics is used in drug development in order to get early pre-clinical indications of efficacy and toxicity.
* Model organisms can also be used for chemical genetics approaches to discover pathways of compound action and this is reiterated with the recognition of systems available in fly, mouse, bug or bacteria.
* The combination of metabonomics, genomic and proteomic data provides potential to seek new disease markers. Non-targeted approaches to metabolic profiling reveal biochemicals that were not previously identified, therefore, leading to diagnostic testing that can be developed around the findings.

Further Information: http://www.marketreports.com/x2443.html